Corina Amor

Corina Amor

Auto-generated profile, based on publicly available information

Corina Amor

Cold spring harbor laboratory, cold spring harbor, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2020 in Nature
Verified
Journal Article
Open access
PDF file
CACorina Amor
Corina Amor
JFJudith Feucht
Judith Feucht
JLJosef Leibold
Josef Leibold
YHYu-Jui Ho
Yu-Jui Ho
CZChangyu Zhu
Changyu Zhu
SLScott W. Lowe
Scott W. Lowe
Cellular senescence is characterized by stable cell-cycle arrest and a secretory program that modulates the tissue microenvironment1,2. Physiologically, senescence serves as a tumour-suppressive mechanism that prevents the expansion of premalignant cells3,4 and has a beneficial role in wound-healing responses5,6. Pathologically, the aberrant accumulation of senescent cells generates an inflammatory milieu that leads to chronic tissue damage and contributes to diseases such as liver and lung fibrosis, atherosclerosis, diabetes and osteoarthritis1,7. Accordingly, eliminating senescent cells from damaged tissues in mice ameliorates the symptoms of these pathologies and even promotes longevity1,2,8,9,10. Here we test the therapeutic concept that chimeric antigen receptor (CAR) T cells that target senescent cells can be effective senolytic agents. We identify the urokinase-type plasminogen activator receptor (uPAR)11 as a cell-surface protein that is broadly induced during senescence and show that uPAR-specific CAR T cells efficiently ablate senescent cells in vitro and in vivo. CAR T cells that target uPAR extend the survival of mice with lung adenocarcinoma that are treated with a senescence-inducing combination of drugs, and restore tissue homeostasis in mice in which liver fibrosis is induced chemically or by diet. These results establish the therapeutic potential of senolytic CAR T cells for senescence-associated diseases.

1 December 2014 in Cell
Verified
Journal Article
Closed access
FMFei-Long Meng
Fei-Long Meng
ZDZhou Du
Zhou Du
AFAlexander Federation
Alexander Federation
JHJiazhi Hu
Jiazhi Hu
Qiao WangQiao Wang
Qiao Wang
FAFrederick W. Alt
Frederick W. Alt

24 January 2024 in Nature Aging
Verified
Journal Article
Open access
PDF file
CACorina Amor
Corina Amor
IFInés Fernández-Maestre
Inés Fernández-Maestre
SCSaria Chowdhury
Saria Chowdhury
YHYu-Jui Ho
Yu-Jui Ho
SNSandeep Nadella
Sandeep Nadella
SLScott W. Lowe
Scott W. Lowe
Senescent cells, which accumulate in organisms over time, contribute to age-related tissue decline. Genetic ablation of senescent cells can ameliorate various age-related pathologies, including metabolic dysfunction and decreased physical fitness. While small-molecule drugs that eliminate senescent cells (‘senolytics’) partially replicate these phenotypes, they require continuous administration. We have developed a senolytic therapy based on chimeric antigen receptor (CAR) T cells targeting the senescence-associated protein urokinase plasminogen activator receptor (uPAR), and we previously showed these can safely eliminate senescent cells in young animals. We now show that uPAR-positive senescent cells accumulate during aging and that they can be safely targeted with senolytic CAR T cells. Treatment with anti-uPAR CAR T cells improves exercise capacity in physiological aging, and it ameliorates metabolic dysfunction (for example, improving glucose tolerance) in aged mice and in mice on a high-fat diet. Importantly, a single administration of these senolytic CAR T cells is sufficient to achieve long-term therapeutic and preventive effects.

1 July 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JLJosef Leibold
Josef Leibold
MRMarcus Ruscetti
Marcus Ruscetti
ZCZhen Cao
Zhen Cao
YHYu-Jui Ho
Yu-Jui Ho
TBTimour Baslan
Timour Baslan
SLScott W. Lowe
Scott W. Lowe
To study genetic factors influencing the progression and therapeutic responses of advanced prostate cancer, we developed a fast and flexible system that introduces genetic alterations relevant to human disease directly into the prostate glands of mice using tissue electroporation. These electroporation-based genetically engineered mouse models (EPO-GEMM) recapitulate features of traditional germline models and, by modeling genetic factors linked to late-stage human disease, can produce tumors that are metastatic and castration-resistant. A subset of tumors with Trp53 alterations acquired spontaneous WNT pathway alterations, which are also associated with metastatic prostate cancer in humans. Using the EPO-GEMM approach and an orthogonal organoid-based model, we show that WNT pathway activation drives metastatic disease that is sensitive to pharmacologic WNT pathway inhibition. Thus, by leveraging EPO-GEMMs, we reveal a functional role for WNT signaling in driving prostate cancer metastasis and validate the WNT pathway as therapeutic target in metastatic prostate cancer. Significance: Our understanding of the factors driving metastatic prostate cancer is limited by the paucity of models of late-stage disease. Here, we develop EPO-GEMMs of prostate cancer and use them to identify and validate the WNT pathway as an actionable driver of aggressive metastatic disease. This article is highlighted in the In This Issue feature, p. 890

4 January 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JLJosef Leibold
Josef Leibold
KTKaloyan M. Tsanov
Kaloyan M. Tsanov
CACorina Amor
Corina Amor
YHYu-Jui Ho
Yu-Jui Ho
FSFrancisco J. Sánchez-Rivera
Francisco J. Sánchez-Rivera
SLScott W. Lowe
Scott W. Lowe
Metastatic gastric carcinoma is a highly lethal cancer that responds poorly to conventional and molecularly targeted therapies. Despite its clinical relevance, the mechanisms underlying the behavior and therapeutic response of this disease are poorly understood owing, in part, to a paucity of tractable models. Here we developed methods to somatically introduce different oncogenic lesions directly into the murine gastric epithelium. Genotypic configurations observed in patients produced metastatic gastric cancers that recapitulated the histological, molecular and clinical features of all nonviral molecular subtypes of the human disease. Applying this platform to both wild-type and immunodeficient mice revealed previously unappreciated links between the genotype, organotropism and immune surveillance of metastatic cells, which produced distinct patterns of metastasis that were mirrored in patients. Our results establish a highly portable platform for generating autochthonous cancer models with flexible genotypes and host backgrounds, which can unravel mechanisms of gastric tumorigenesis or test new therapeutic concepts.

25 November 2025 in Nature Aging
Verified
Journal Article
Open access
PDF file
OEOnur Eskiocak
Onur Eskiocak
JGJoseph Gewolb
Joseph Gewolb
VSVyom Shah
Vyom Shah
JRJames A. Rouse
James A. Rouse
SCSaria Chowdhury
Saria Chowdhury
CACorina Amor
Corina Amor
Intestinal stem cells (ISCs) drive the rapid regeneration of the gut epithelium. However, during aging, their regenerative capacity wanes, possibly through senescence and chronic inflammation, albeit little is known about how aging-associated dysfunction arises in the intestine. We previously identified the urokinase plasminogen activator receptor (uPAR) as a senescence-associated protein and developed CAR T cells able to efficiently target it. Harnessing them, here, we identify the accumulation of mostly epithelial uPAR-positive cells in the aging gut and uncover their detrimental impact on ISC function in aging. Thus, both therapeutic and prophylactic treatment with anti-uPAR CAR T cells improved barrier function, regenerative capacity, inflammation, mucosal immune function and microbiome composition in aged mice. Overall, these findings reveal the deleterious role of uPAR-positive cells on intestinal aging in vivo and provide proof of concept for the potential of targeted immune-based cell therapies to enhance tissue regeneration in aging organisms.